Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average (2016 - 2025)

Historic Equity Average for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $471.3 million.

  • Ani Pharmaceuticals' Equity Average fell 249.16% to $471.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.3 million, marking a year-over-year decrease of 249.16%. This contributed to the annual value of $458.9 million for FY2024, which is 2.41% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Equity Average stood at $471.3 million, which was down 249.16% from $427.7 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Equity Average registered a high of $483.3 million during Q3 2024, and its lowest value of $191.7 million during Q3 2021.
  • For the 5-year period, Ani Pharmaceuticals' Equity Average averaged around $381.6 million, with its median value being $401.6 million (2022).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 10725.22% in 2022, then tumbled by 1488.16% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Equity Average stood at $289.6 million in 2021, then surged by 38.68% to $401.6 million in 2022, then grew by 17.51% to $472.0 million in 2023, then fell by 3.11% to $457.3 million in 2024, then grew by 3.06% to $471.3 million in 2025.
  • Its Equity Average stands at $471.3 million for Q3 2025, versus $427.7 million for Q2 2025 and $411.2 million for Q1 2025.